Creative Realities (NASDAQ:CRDF) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares Creative Realities and Cortexyme’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Creative Realities||$250,000.00||390.94||-$16.41 million||($2.80)||-1.81|
This table compares Creative Realities and Cortexyme’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
4.6% of Creative Realities shares are owned by institutional investors. Comparatively, 27.4% of Cortexyme shares are owned by institutional investors. 0.6% of Creative Realities shares are owned by company insiders. Comparatively, 19.8% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Creative Realities and Cortexyme, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Creative Realities presently has a consensus price target of $6.00, suggesting a potential upside of 18.11%. Cortexyme has a consensus price target of $68.33, suggesting a potential upside of 51.85%. Given Cortexyme’s higher possible upside, analysts plainly believe Cortexyme is more favorable than Creative Realities.
Cortexyme beats Creative Realities on 8 of the 11 factors compared between the two stocks.
Creative Realities Company Profile
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Cortexyme Company Profile
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for Creative Realities Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Realities and related companies with MarketBeat.com's FREE daily email newsletter.